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Background: Despite the significant contributions of monocytes to HIV persistence, the HIV-monocyte interaction
remains elusive. For patients on antiretroviral therapy, previous studies observed a virological suppression rate of
>70% and suggested complete viral suppression as the primary goal. Although some studies have reported genetic
dysregulations associated with HIV disease progression, research on ex vivo-derived monocytic transcriptomes from
HIV+ patients with differential responses to therapy is limited. This study investigated the monocytic transcriptome
distinctions between patients with sustained virus suppression and those with virological failure during highly active
antiretroviral therapy (HAART).
Methods: Genome-wide transcriptomes of primary monocytes from five HIV+ patients on HAART who sustainably
controlled HIV to below detection level (BDL), five HIV+ patients on HAART who consecutively experienced viremia,
and four healthy HIV sero-negative controls were analyzed using Illumina microarray. Pairwise comparisons were
performed to identify differentially expressed genes followed by quantitative PCR validation. Gene set enrichment
analysis was used to check the consistency of our dataset with previous studies, as well as to detect the global
dysregulations of the biological pathways in monocytes between viremic patients and BDLs.
Results: Pairwise comparisons including viremic patients versus controls, BDL versus controls, and viremic patients
versus BDLs identified 473, 76, and 59 differentially expressed genes (fold change > 2 and FDR < 0.05), respectively.
The reliability of our dataset was confirmed by gene set enrichment analysis showing that 6 out of 10 published
gene lists were significantly enriched (FDR < 0.01) in at least one of the three pairwise comparisons. In the
comparison of viremic patients versus BDLs, gene set enrichment analysis revealed that the pathways characterizing
the primary functions of monocytes including antigen processing and presentation, FcγR mediated phagocytosis,
and chemokine signaling were significantly up-regulated in viremic patients.
Conclusions: This study revealed the first transcriptome distinctions in monocytes between viremic patients and
BDLs on HAART. Our results reflected the outcome balanced between the subversion of the monocyte
transcriptome by HIV and the compensatory effect adapted by host cells. The up-regulation of antigen presentation
pathway in viremic patients particularly highlighted the role of the interface between innate and adaptive immunity
in HIV disease progression.
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Monocytes, a key cell type in innate and adaptive immun-
ity, have a propensity to differentiate into macrophages or
dendritic cells [1,2]. This differentiation ability, along with
the activities of antigen presentation, migration, chemo-
taxis, and phagocytosis [3], enables them to play crucial
roles in HIV pathogenesis. Though less permissive to HIV
infection than T cells and macrophages [4,5], monocytes
could be infected by HIV [6,7] and infectious virus can be
isolated from circulating monocytes in untreated patients
and highly active antiretroviral therapy (HAART) re-
sponders [4,8]. By harboring and trafficking HIV into
various tissue compartments through differentiating into
tissue macrophages or dendritic cells, monocytes serve as
important viral reservoirs [9,10]. During therapy, mono-
cytes can maintain HIV replication throughout HAART as
antiretroviral drugs may not block viral replication in
monocytes as efficiently as they do in CD4+ T cells [10].
Moreover, undifferentiated monocytic precursor cells
(such as CD34+ progenitor cells) infected by HIV may
pass the virus to progeny monocytes and keep on renew-
ing the viral pool in peripheral blood monocytes [11,12].
Despite the significant contributions of monocytes to
HIV persistence, the underlying pathogenic mechanism
is not fully understood. To better understand HIV patho-
genesis at the genomic level, genome-wide transcriptomic
studies of monocytes and monocyte-derived macrophages
(MDM) have been carried out. For example, studies using
monocytes/MDM infected by HIV in vitro revealed the key
areas of monocyte dysfunctions related to inflammation
[13], cytokine networks [14], cell cycle [15], cytoskeleton
[16], and signaling pathways [17,18]. Other studies using
ex vivo-derived monocytes identified an anti-apoptosis
gene signature in viremic patients [19], a mixed phenotype
with both increased and decreased pro-inflammatory fea-
tures in patients with high viral load [20,21], and a novel
candidate gene NAMPT correlating with the viral load in
therapy-naïve patients [22]. Recently, by comparing the
monocyte transcriptomes from HIV+ progressors and ther-
apy naïve non-progressors, we have shown the systematic
alteration of the interrelated pathways such as Toll-like
receptor (TLR) signaling and cytokine-cytokine receptor
interaction in viremic patients [23]. Although these studies
have provided large datasets to facilitate our understand-
ing, current knowledge on the dysregulations of monocytic
transcriptome during HIV disease progression remains far
from complete. In particular, none of the previous studies
has looked into the global dysregulations of the biological
pathways in monocytes from patients with sustained virus
suppression versus those with virological failure during
HAART, as we previously did on T cell subsets [24]. Re-
garding the virological suppression rate by HAART, the
study on the patients receiving HAART for 12 months in
Nigeria has observed a virological suppression rate of76.7% versus a virological failure rate of 23.4% [25],
whereas another study on the UK cohort has reported that
73.5% of the patients initiating HAART achieved complete
virological suppression within 6 months [26].
In order to get a better insight into the dysregulations
of monocytic transcriptomes from HIV+ patients with
differential responses to antiretroviral therapy, this study
analyzed transcriptomes of primary circulating mono-
cytes from HIV+ patients on HAART who sustainably
controlled HIV to below detection level (BDL), HIV+ pa-
tients on HAART who consecutively experienced viremia
(VIR), and 4 sero-negative controls (CTR; Table 1) using
Illumina HumanHT-12 v3 Expression BeadChip. Our ana-
lysis at the gene set level has shown that in the compari-
son of VIR versus BDL, the pathways characterizing the
primary functions of monocytes including antigen pro-
cessing and presentation, FcγR mediated phagocytosis,
and chemokine signaling were significantly up-regulated
in the VIR group. These results reflected the outcome
balanced between the subversion of monocyte transcrip-
tome by HIV and the compensatory effect adapted by
host cells during disease progression following therapy.
In particular, the up-regulation of antigen presentation
pathway in the VIR group highlighted the role of the
interface between innate and adaptive immunity in HIV
disease progression.
Results
Cluster analysis and identification of differentially
expressed genes
Genome-wide transcriptomes of primary monocytes
from 5 HIV+ patients on HAART who consecutively ex-
perienced viremia, 5 HIV+ patients on HAART who sus-
tainably controlled HIV to below detection level, and 4
healthy HIV sero-negative controls (5 VIR, 5 BDL, and 4
CTR; Table 1) were analyzed using Illumina microarray.
The hierarchical clustering analysis revealed that the VIR
group formed an independent cluster from the BDL
group and these HIV+ groups further combined into a
distinct cluster from the CTR group (Figure 1). Pairwise
comparisons between the three groups were carried out
and differentially expressed genes (DEGs) with FDR < 0.05
and fold change > 2 were identified for each comparison.
For the comparison of VIR versus CTR, 473 DEGs were
identified (324 up-regulated and 149 down-regulated;
Additional file 1). For the comparison of BDL versus CTR,
76 DEGs were found (45 up-regulated and 31 down-
regulated; Additional file 1). When the VIR group was
compared to the BDL group, 59 DEGs were detected (48
up-regulated and 11 down-regulated; Table 2). These 59
DEGs were uploaded to DAVID (Database for Annotation,
Visualization, and Integrated Discovery) for the detection
of DEGs overlapping with the genes in HIV interaction
database [23]. Fourteen DEGs were present in HIV
Table 1 Clinical profiles of study patients
Patient Group Age Gender Viral load (copies/ml) CD4 (cells/μl) CD8 (cells/μl) Total months on HAART RNA integrity number
VIR1 VIR 54 F 87 418 473 14.8 10
VIR2 VIR 52 M 787 286 916 19.7 9.8
VIR3 VIR 31 F 194 300 548 23.2 9.9
VIR4 VIR 49 M 177 674 1131 14.3 10
VIR5 VIR 33 M 169 100 861 15.8 10
BDL1 BDL 45 M < 40 796 1958 18.5 10
BDL2 BDL 48 F < 40 459 1250 14.2 10
BDL3 BDL 43 F < 40 427 569 24.0 10
BDL4 BDL 57 M < 40 384 1728 14.3 10
BDL5 BDL 37 M < 40 241 587 16.9 9.9
VIR1-5: patients on HAART consecutively experiencing viremia (viral load <1,000); BDL1-5: patients on HAART with sustained below detection level of plasma viral
load (viral load < 40 copies of HIV RNA/ml).
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which gave the initial confirmation of the reliability of our
dataset at the discrete gene level (Additional file 2).
qPCR validation and the comparison to previous
microarray studies
To further confirm the DEGs from microarray analysis,
mRNA expression levels of the selected DEGs were mea-
sured by quantitative PCR (qPCR; Table 3). The DEGs
were selected based on the coverage of different levels
and directions of fold change, different ranges of FDR
values, and/or biological significance. The cohort for
qPCR validation consisted of 10 viremic patients, 10
BDLs, and 9 healthy controls (including all the original
samples used in the microarray). The fold changes for
each pairwise comparison evaluated by qPCR were fully
consistent with the results obtained from microarray,
which confirmed the reliability of our microarray data.Figure 1 Clustering analysis of gene expression profiles of monocyte
for controls.We then compared our dataset with published DEG lists
derived from the studies on monocyte/MDM transcrip-
tomes modulated by HIV since 2002 [15,16,19,21,22,27-30].
The GSEA showed that in our transcriptome dataset, 6
out of the 10 published gene lists were significantly
enriched (FDR < 0.01, the most stringent cut off ) in at
least one of the 3 pairwise comparisons, whereas the
remaining 4 gene lists reached the relaxed significance
level (FDR < 0.25) in all of the 3 pairwise comparisons
(Table 4). Nevertheless, the highly significant enrich-
ment of the majority of these gene lists (FDR < 0.01)
demonstrated general consistency of our data with pre-
vious studies.
Pathway analysis by GSEA
As we aimed to identify monocyte dysfunction in rela-
tion to HIV disease progression, our subsequent path-
way analysis focused on the comparison between VIRs. The label V represents for viremic patients, B for BDLs, and C
Table 2 Differentially expressed genes in the comparison of VIR versus BDL
ProbeID Gene symbol Entrez gene name logFC FDR
4540239 DEFA1 Defensin, alpha 1 −2.06 0.018
2970747 DEFA3 Defensin, alpha 3 −1.74 0.012
7150170 LOC728358 NA −1.54 0.020
50088 HCFC1R1 Host cell factor C1 regulator 1 (XPO1 dependent) −1.47 0.003
2750647 C20orf27 Chromosome 20 open reading frame 27 −1.17 0.005
3390068 E4F1 E4F transcription factor 1 −1.09 0.003
4280661 TMUB2 Transmembrane and ubiquitin-like domain containing 2 −1.08 0.003
2490333 ZNF467 Zinc finger protein 467 −1.06 0.036
1820053 SLC43A2 Solute carrier family 43, member 2 −1.05 0.010
6940647 C16orf58 Chromosome 16 open reading frame 58 −1.01 0.034
1570255 DEF6 Differentially expressed in FDCP 6 homolog (mouse) −1.00 0.017
2630017 TPST2 Tyrosylprotein sulfotransferase 2 1.00 0.027
5810008 DLGAP4 Discs, large (Drosophila) homolog-associated protein 4 1.01 0.017
4050475 KIAA0319L KIAA0319-like 1.01 0.048
730632 LSP1 Lymphocyte-specific protein 1 1.02 0.017
7160711 MAP2K3 Mitogen-activated protein kinase kinase 3 1.02 0.020
4200025 OAF OAF homolog (Drosophila) 1.02 0.008
1510414 MGRN1 Mahogunin ring finger 1, E3 ubiquitin protein ligase 1.04 0.017
2490072 PRAM1 PML-RARA regulated adaptor molecule 1 1.04 0.020
7320494 ZFPM1 Zinc finger protein, FOG family member 1 1.04 0.003
6450092 C5AR1 Complement component 5a receptor 1 1.05 0.031
7570068 EP300 E1A binding protein p300 1.05 0.044
770168 CLPTM1 Cleft lip and palate associated transmembrane protein 1 1.06 0.005
1070044 GMIP GEM interacting protein 1.06 0.017
7400053 SLC22A18 Solute carrier family 22, member 18 1.06 0.041
3800307 SHKBP1 SH3KBP1 binding protein 1 1.07 0.005
830750 NCF1B Neutrophil cytosolic factor 1B pseudogene 1.07 0.012
7050484 ZYX Zyxin 1.08 0.008
4640064 LTBR Lymphotoxin beta receptor (TNFR superfamily, member 3) 1.08 0.008
2000224 FAM89B Family with sequence similarity 89, member B 1.09 0.018
1940021 GRN Granulin 1.09 0.017
2480288 GPAA1 Glycosylphosphatidylinositol anchor attachment 1 1.09 0.022
2970356 ALDH3B1 Aldehyde dehydrogenase 3 family, member B1 1.13 0.005
5570767 PPP2R1A Protein phosphatase 2, regulatory subunit A, alpha 1.13 0.006
5890072 TRAPPC9 Trafficking protein particle complex 9 1.14 0.001
6960026 STXBP2 Syntaxin binding protein 2 1.14 0.000
5910019 C1QB Complement component 1, q subcomponent, B chain 1.17 0.019
270437 ACTN4 Actinin, alpha 4 1.18 0.000
5570242 PFKL Phosphofructokinase, liver 1.20 0.004
840669 LOC654346 NA 1.22 0.017
4920546 ARSA Arylsulfatase A 1.24 0.001
2650092 JOSD2 Josephin domain containing 2 1.25 0.000
4760255 ARHGDIA Rho GDP dissociation inhibitor (GDI) alpha 1.26 0.004
6480333 TCIRG1 T-cell, immune regulator 1, ATPase, H + transporting, lysosomal V0 subunit A3 1.29 0.001
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Table 2 Differentially expressed genes in the comparison of VIR versus BDL (Continued)
4180494 ITGAL Integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated
antigen 1; alpha polypeptide)
1.30 0.010
6620609 ABTB1 Ankyrin repeat and BTB (POZ) domain containing 1 1.30 0.021
150154 FAM108A3 Family with sequence similarity 108, member A3, pseudogene 1.30 0.000
4730349 PNKD Paroxysmal nonkinesigenic dyskinesia 1.31 0.040
2140392 ZNF580 Zinc finger protein 580 1.32 0.006
4890068 MAP3K11 Mitogen-activated protein kinase kinase kinase 11 1.32 0.001
7550500 JUNB Jun B proto-oncogene 1.39 0.028
7650128 ECGF1 Thymidine phosphorylase 1.40 0.012
4220603 SPI1 Spleen focus forming virus (SFFV) proviral integration oncogene spi1 1.43 0.005
5090632 LGALS9 Lectin, galactoside-binding, soluble, 9 1.45 0.006
20673 BSG Basigin (Ok blood group) 1.61 0.000
770754 TTYH3 Tweety homolog 3 (Drosophila) 1.72 0.001
6580059 UCP2 Uncoupling protein 2 (mitochondrial, proton carrier) 1.79 0.023
130403 RNF19B Ring finger protein 19B 1.83 0.004
6370315 HLA-DRB5 Major histocompatibility complex, class II, DR beta 5 5.66 0.012
The differentially expressed genes were sorted by fold change.
Gene symbols in italic indicated genes in HIV interaction database.
FDR: false discovery rate; NA: not available.
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pathways including 186 gene sets. Unlike DEG approach,
GSEA uses the whole gene expression dataset to identify
enriched pathways and is better able to detect small co-
ordinated changes in gene expression in the context of
gene set [31,32].
In the comparison of VIR versus BDL, 26 pathways
were significantly up-regulated in the VIR group (FDR <
0.05/stringent cut off; Additional file 3), whereas no
pathway down-regulated in the VIR group passed this
threshold. These 26 significantly up-regulated pathways
can be grouped into 3 functional categories including
immune-related pathways (n = 10), disease (n = 10), and
metabolism pathways (n = 6; Table 5; Additional file 3).Table 3 qPCR confirmation of differentially expressed genes
Gene Comparison qPCR Microarray
ACTN4 VIRvsCTR 3.1 3.6
ACTN4 VIRvsBDL 1.8 2.3
ITGAL VIRvsCTR 1.9 2.4
ITGAL VIRvsBDL 2.3 2.5
GNAI2 VIRvsCTR 2.7 2.9
SERPING1 VIRvsCTR 3.8 2.6
IL8 VIRvsCTR −4.6 −5.0
Fold change by qPCR was obtained from the mean expressions of the tested genes
patients, 10 BDLs, and 9 healthy controls (including all the original samples used in
of the first group versus expression levels of the second group. Minus sign indicate
regulation in the first group. Housekeeping gene GAPDH was used as an internal coWe chose to focus on the immune-related pathways as
they have the most direct relevance to the immune dys-
function of monocytes.
Out of the ten immune-related pathways (Table 5), two
were involved in cell differentiation and development
(hematopoietic cell lineage and neurotrophin signaling),
two were associated with transendothelial migration (cell
adhesion molecules and adherens junctions), and the
remaining six covered all the major aspects of innate
immunity, including chemokine signaling, IgA produc-
tion, complement cascade, phagocytosis, lysosome, and
antigen presentation. All the core enrichment genes
contributing to the up-regulation of the immune-related
pathways are listed in Table 5. Since the pathways ofGene Comparison qPCR Microarray
IL1B VIRvsCTR −12.5 −13.2
IL1B BDLvsCTR −17.0 −20
CSK VIRvsCTR 3.7 2.9
CFL1 VIRvsCTR 2.5 2.2
CD37 VIRvsCTR 2.3 2.4
C1QB VIRvsBDL 2.6 2.3
C1QB VIRvsCTR 4.1 4.3
in each group. The cohort for qPCR validation consisted of 10 viremic
the microarray). All values represent fold changes between expression levels
s down-regulation in the first group whereas positive sign indicates up-
ntrol and the normalizer in qPCR.
Table 4 The GSEA of our dataset compared with the published gene lists derived from monocyte/MDM transcriptomes
modulated by HIV
Gene set name Pathways/biological
functions DEGs involved in
HIV infection/disease
progression








Cicala_Cytokine _Chemokine Chemokine and cytokine in vitro gp120-treated vs
mock-treated MDM






in vitro HIV-infected vs
mock-treated MDM
[15] 38 0.07* 0.192* 0.226*
Woelk_InteferonStimuated Interferon stimulated genes,
host defense genes
in vitro HIV-infected vs
mock-treated MDM
[30] 12 0.004*** 0.000*** 0.007***
Vazquez_HIVinduced _MDM Signal transduction,






in vitro HIV-infected vs
mock-treated MDM
[28] 124 0.059* 0.096* 0.159*
Wen_HIVvsMock_U937 Signaling components,
transcription factors,
cytokines, apoptotic and anti-
apoptotic factors, growth fac-
tors, anti-HIV infection genes
in vitro HIV-infected vs
mock-infected U937 hu-
man promonocytes
[29] 33 0.094* 0.008*** 0.004***
TILTON_CytokineLevel
_Correlation
Type I interferon responses,
NF-κB, mitogen-activated











in HIV+ patients on and
off therapy
[21] 1295 0.222* 0.161* 0.156*




ex vivo HIV+ patients vs
healthy controls







ex vivo HIV+ patients vs
healthy controls





signature TNF (NFκB), p53
and MAPK networks




[27] 62 0.229* 0.008*** 0.015**
Gekonge_HIVvsControl ERK/MAPK, TNF/IL6 (NFκB)
and p53 gene networks,
apoptosis-related gene
signatures
ex vivo HIV+ patients vs
healthy controls
[27] 281 0.138* 0.066* 0.061*
DEGs: differentially expressed genes; gene set size: number of genes in the published list; FDR: false discovery rate; VIR: the viremic patients; CTR: the healthy
control group; MDM: monocyte-derived macrophages; vs: versus. *FDR < 0.25 (default cutoff); **FDR < 0.05(more stringent); ***FDR < 0.01(most stringent).
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naling characterize the primary functions of monocytes,
we further inspected their core enrichment genes.
Up-regulation of antigen presentation pathway in VIR
versus BDL
The antigen processing and presentation pathway
(HSA04612) was significantly up-regulated in the VIR
group compared to the BDL group (FDR = 0.016). The
enrichment plot and the heat map of the core enrichmentgenes for antigen presentation pathway are displayed as
representatives to illustrate the GSEA output in Figure 2.
Figure 2B shows not only the coordinated up-regulation
of these core enrichment genes in the VIR group as a
combination from all the viremic patients, but also the
variations in gene expression between subjects within each
group. For example, while VIR2 had lower expression of
the core enrichment genes than VIR1, VIR2 still exhibited
higher expression than the majority of the patients from
the BDL group. Nineteen out of 88 gene members of this
Table 5 The ten immune-related pathways significantly up-regulated in viremic patients versus BDLs








88 0.00 0.016 HLA-DRB5, HLA-DRB1, CD4, HLA-C, IFI30, NFYC, TAPBP, HSPA1B,
CD74, HLA-DOA, TAP2, HLA-E, PDIA3, PSME1, HSP90AB1, RFX5,
CALR, KIR2DS5, HLA-F
KEGG_ADHERENS_JUNCTION 73 0.00 0.016 ACTN4, EP300, TCF7L2, PTPN6, IQGAP1, CSNK2B, SRC, FYN, RAC1,
CSNK2A2, WASF2, PVRL4, PTPN1, BAIAP2, CTNNB1, PVRL2, ACTB
KEGG_HEMATOPOIETIC_CELL_ LINEAGE 87 0.00 0.016 HLA-DRB5, HLA-DRB1, FLT3LG, CD4, TNF, CD37, IL1B, CD9, CD36,
EPOR, ANPEP, CD1A, CD19, ITGA2B, FCER2, CD1D, FCGR1A
KEGG_CELL_ADHESION_ MOLECULES_CAMS 134 0.00 0.017 HLA-DRB5, HLA-DRB1, ITGAL, ITGB7, CD40, CD4, HLA-C, SELL,
PECAM1, SPN, HLA-DOA, ICAM2, HLA-E, ICAM3, CLDN3, PVRL2,
JAM3, HLA-F, CD28, CLDN18, PVR, CD99, ICOS, PDCD1LG2, CD80,
CLDN5, NEO1, PDCD1, ITGAM, PTPRF, HLA-DRA, CNTN2, HLA-B,
CD58, NLGN3, CTLA4, ITGA4, SIGLEC1
KEGG_LYSOSOME 119 0.00 0.023 ARSA, ACP2, SGSH, CTSZ, MCOLN1, CTSA, CTSD, SORT1, FUCA1,
MAN2B1, GBA, TCIRG1, NAPSA, IDUA, NAGPA, M6PR, ATP6V0D1,
NEU1, ACP5, GGA1, LAPTM5, CD63, AP1S1, AP3B1, AP3D1, NAGA,
CLN3, IDS, TPP1
KEGG_NEUROTROPHIN_ SIGNALING_PATHWAY 125 0.00 0.025 YWHAE, ARHGDIA, RPS6KA4, SH2B2, MAP2K2, MAPKAPK2, MAPK7,
SORT1, CSK, RELA, SHC1, PIK3CG, KIDINS220, CRK, IRAK1, BAX,
SH2B3, RAC1, MAP2K5, AKT1, CALM1, MAP3K3, MAPK9, ABL1,
RPS6KA3, SH2B1, IRS1, RAF1, HRAS, MAPK14
KEGG_FC_GAMMA_R_MEDIATED_PHAGOCYTOSIS 92 0.00 0.029 MARCKSL1, NCF1, PIP5K1C, VASP, HCK, PIK3CG, DNM2, CRK, SYK,
ARPC4, ARPC1A, SPHK1, RAC1, ARPC5L, LYN, AKT1, WASF2, VAV1,
ARPC1B, LOC653888, FCGR1A, RAF1, PRKCA, GSN, DNM1, PAK1,
VAV2, CFL1, AKT2
KEGG_CHEMOKINE_SIGNALING_ PATHWAY 185 0.00 0.038 PLCB2, NCF1, GNB2, ELMO1, CX3CR1, GRK6, PPBP, GNAI2, CSK,
GNB4, RELA, SHC1, HCK, ARRB1, PIK3CG, CRK, RASGRP2, CCR1,
GNGT2, GNG5, GNG3, STAT5B, RAC1, LYN, AKT1, CCL2, JAK2,
VAV1, GNG8, CCR2, CCR9, PRKACA, CCR7, XCR1, TIAM2, GNG12,
RAF1, ARRB2, HRAS, CXCR5, PTK2B, PAK1, CCR3, VAV2
KEGG_COMPLEMENT_AND_ COAGULATION_
CASCADES
68 0.01 0.038 C1QB, C1QC, C5AR1, SERPING1, C1QA, C2, KLKB1, C3AR1, THBD,
SERPINA1, C4A, SERPINA5
GS size: Gene set size (number of genes in a particular gene set); NOM p-val: nominal p value; FDR: false discovery rate.
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which included 6 MHC molecules (MHC I: HLA-C,
HLA-E, and HLA-F; MHC II: HLA-DOA, HLA-DRB1,
and HLA-DRB5); 2 transcription factors associated with
MHC transcription (NFYC and RFX5), 4 molecules re-
lated to antigen digestion (MHC I: PSME1/PA28 alpha,
HSP90AB1, HSPA1B/HSP70; MHC II: IFI30/GILT), 5
molecules involved in antigen transport and loading
(MHC I: TAP2 and TAPBP, CALR, and PDIA3/BRp57;
MHC II: CD74/CLIP), and 2 cell surface molecules (CD4
and KIR2DS5).
Up-regulation of phagocytosis pathway in VIR versus BDL
FcγR-mediated phagocytosis (HSA04666) was signifi-
cantly up-regulated in the VIR group versus the BDL
group (FDR = 0.029). It was exemplified by the increased
Fc receptor expression (FCGR1A), the up-regulation of
SRC kinases (LYN and HCK) coupled with receptor
binding, and the subsequently triggered kinases activat-
ing a range of downstream effectors (Table 5). Figure 4shows that the majority of these 29 core enrichment
genes (92 genes in total) spread along the arms of SYK -
PI3K - AKT/Dynamin, SPHK - PRKCA (cPKC) - SPHK1
(NADPH oxidase involved in microorganism digestion),
PIP5K - VASP/WASP - ARP2/3 (actin related protein),
and VAV/CRKII – RAC - PAK1 - CFL1 (Cofilin, an actin-
modulating protein). The end effectors were involved in
both cytoskeleton rearrangement crucial for phagosome
formation (ARP2/3, MARCKS, Gelsolin, Cofilin, and Dyna-
min) and the release of reactive oxygen species (p47phox)
for microorganism degradation.
Up-regulation of chemokine signaling pathway in VIR
versus BDL
Forty-four out of 185 members of chemokine signaling
pathway (HSA04062) were coordinately up-regulated (core
enrichment genes) in the VIR group versus the BDL group
(FDR = 0.038; Table 5; Figure 5). Nine genes were involved
in receptor interaction including 8 chemokine receptors
(CCR1, CCR2, CCR3, CCR7, CCR9, CX3CR1, CXCR5, and
Figure 2 Enrichment plot and heat map for the gene set of antigen processing and presentation pathway by GSEA. A. Enrichment plot
for monocytes from the VIR group (VIR versus BDL). Bottom, plot of the ranked list of all genes. Y axis, value of the ranking metric; X axis, the
rank for all genes. Genes whose expression levels are most closely associated with the VIR or BDL group get the highest metric scores with
positive or negative sign, and are located at the left or right edge of the list. Middle, the location of genes from the antigen processing and
presentation pathway within the ranked list. Top, the running enrichment score for the gene set as the analysis walks along the ranked list. The
score at the peak of the plot is the enrichment score (ES) for this gene set and those genes appear before or at the peak are defined as core
enrichment genes for this gene set. B. Heat map of the core enrichment genes corresponding to A. The genes that contribute most to the ES, i.
e., genes that appear in the ranked list before or at the peak point of ES, are defined as core enrichment genes. Rows, genes; columns, samples.
Range of colors (red to blue) shows the range of expression values (high to low).
Wu et al. Virology Journal 2013, 10:361 Page 8 of 16
http://www.virologyj.com/content/10/1/361XCR1) and 1 chemokine ligand (CCL2). Three genes were
associated with receptor deactivation (GRK, ARRB1 and
ARRB2/β-arrestin) and 8 were G proteins (GNAI2, GNB2,
GNB4, GNG12, GNG3, GNG5, GNG8, and GNGT2),
which initiated subsequent signaling cascades. The Gα sub-
unit triggered signaling through three arms including SRC
(SCK and LYN) – PI3K (PIK3CG) – AKT (AKT1) – NFκB
(RELA), SHC (SHC1) – RAS (HRAS) – RAF (RAF1;
MAPK pathway), and PYK2 – CRK. The Gβ subunit not
only activated PLCβ (PLCB2) which led to reactive oxygen
species production (p47phox), but also signaled through
RAC1 and PAK1 resulting in regulation of actin cytoskel-
eton. The signaling arm of JAK2 – STAT5B was also up-
regulated.
Promoter motif analysis by GSEA
Promoter motif analysis by GSEA used gene sets that
contained gene members sharing the same transcription
factor binding site defined in the TRANSFAC database
[33]. This analysis can identify the coordinated changes
of the genes under the control of a certain transcrip-
tional regulator. The GSEA revealed that 37 and 42 genesets were significantly up- and down- regulated in the
VIR group (FDR < 0.05) compared to the BDL group
(Additional file 4). While the majority of the significantly
altered gene sets contained regulatory motifs matching
for the annotated transcription factors, 12 gene sets
contained motifs which did not match any known tran-
scription factor. The most significantly up- and down-
regulated gene sets in the VIR group (both FDR = 0.03)
had gene members sharing the regulatory motif for tran-
scription factors NFκB and MYC, respectively.
Discussion
Our study has provided the first snapshot into the tran-
scriptome distinctions of the primary monocytes between
HIV+ patients on HAART who consecutively experienced
viremia and HIV+ patients on HAART who sustainably
controlled HIV to below detection level (Table 1). The
main objective of the study was to identify genomic signa-
tures associated with HIV disease progression. The rele-
vance of the identified DEGs was initially confirmed by
querying HIV interaction database using DAVID (Table 2;
Additional file 2). The comparison between our dataset
Figure 3 Coordinately up-regulated genes of antigen processing and presentation pathway in monocytes from the VIR group (VIR
versus BDL). The pathway figure is adapted from Kyoto Encyclopedia of Genes and Genomes (KEGG; http://www.genome.jp/kegg/). The proteins
encoded by the coordinately up-regulated genes in the VIR group are highlighted in red.
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http://www.virologyj.com/content/10/1/361and previous microarray studies on monocyte/MDM tran-
scriptomes further confirmed the reliability of our data
(Table 4). The previously identified gene sets, which were
highly significant (FDR < 0.01) in our dataset, reflected the
altered biological functions including cytokine networks,
cell cycle, signaling pathways, metabolism, immune re-
sponses, and transcriptional regulation. These biological
themes were also represented by the gene sets which only
reached the relaxed significance threshold (FDR < 0.25).
The failure of these gene sets to achieve higher statistical
cut-offs could possibly be attributed to certain biological
and/or technical variations across multiple microarray
studies. For example, differences in the cohort such as age,
gender, and ethnicity could contribute to the biological var-
iations, whereas microarray inter-platform differences
could contribute to the technical variations. Compared to
DEG approach which focused on discrete genes, GSEA en-
abled a more comprehensive detection of genes contribut-
ing to the enrichment of the pathways correlated with
disease progression. Therefore, the subsequent discussion
focused on the pathways significantly associated withprogressive phase of HIV disease revealed by GSEA. Since
the immune-related pathways have the most direct rele-
vance to HIV disease and this aspect has been under
constant investigations, our subsequent discussions shall
center on the immune-related pathways including antigen
presentation, phagocytosis, and chemokine signaling.
At the transcriptome level, we observed an overall up-
regulation of antigen processing and presentation pathway
in the VIR group compared to the BDL group (FDR =
0.016; Figure 3; Table 5), which was manifested by the up-
regulation of both endogenous (MHC-I) and exogenous
(MHC-II) signaling branches. Five molecules from MHC-
II pathway were detected as core enrichment genes
including IFI30, CD74, HLA-DOA, HLA-DRB1, and
HLA-DRB5 (Table 5). The coordinated up-regulation of
HLA-DR was consistent with the previous studies report-
ing higher expression levels of surface HLA-DR on mono-
cytes from HIV+ individuals compared to sero-negative
controls [34-36]. As for the MHC-I pathway, the majority
of the core enrichment genes were reported to have inter-
actions with HIV, such as HSP90AB1 [37] and PA28
Figure 4 Coordinately up-regulated genes of FcγR mediated phagocytosis pathway in monocytes from the VIR group (VIR versus BDL).
The pathway figure is adapted from Kyoto Encyclopedia of Genes and Genomes (KEGG; http://www.genome.jp/kegg/). The proteins encoded by
the coordinately up-regulated genes in the VIR group are highlighted in red.
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http://www.virologyj.com/content/10/1/361(PSME1) [38]. Moreover, 3 MHC-I molecules including
HLA-C, HLA-E, and HLA-F were also detected as core
enrichment genes with the coordinated up-regulation in
the viremic patients. The importance of HLA-C was
highlighted in a very recent study showing that increased
HLA-C expression was correlated with increased likeli-
hood of cytotoxic T lymphocyte (CTL) responses and
frequency of viral escape mutation [39]. In addition, the
substantially increased expression of MHC-I including
HLA-C has been reported in monocytes in HIV progres-
sors compared to HAART-suppressed patients, which was
suggested to contribute to the generation of the dysfunc-
tional naive CD8-low T cells that emerged during disease
progression [40]. Taken together, our observation that the
up-regulation of HLA-C expression on monocytes was as-
sociated with plasma viremia could possibly reflect a com-
pensatory effect imposed by impaired CTL responses.
However, this compensatory effect may be subverted by
HIV, resulting in further CD8+ T cell dysfunction as pro-
posed by Favre et al. [40].As antigen presentation pathway is right at the interface
between innate and adaptive immunity, its significant up-
regulation in the viremic patients provides direct evidence
that adaptive immune response is perturbed through the
components of innate immunity during HIV disease pro-
gression. This interference is systematic throughout the
process of antigen presentation as demonstrated by the
core enrichment genes covering not only the aforemen-
tioned MHC molecules, but also the genes associated with
antigen digestion, loading and transportation (Table 5). In
fact, the dysregulation of antigen presentation pathway is
not the only pathway altered at the interface. Other innate
immunity pathways crucial for the development of adap-
tive immunity have also been associated with HIV disease
progression by this and previous studies [23,24,41]. For
example, this study detected that complement cascade
regulating both B and T cell responses [42] was signifi-
cantly up-regulated in the viremic patients (Table 5).
Consistently, complement pathway was also found to be
up-regulated in the viremic patients versus BDLs by our
Figure 5 Coordinately up-regulated genes of chemokine signaling pathway in monocytes from the VIR group (VIR versus BDL). The
pathway figure is adapted from Kyoto Encyclopedia of Genes and Genomes (KEGG; http://www.genome.jp/kegg/). The proteins encoded by the
coordinately up-regulated genes in the VIR group are highlighted in red.
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http://www.virologyj.com/content/10/1/361previous study on primary CD4+ T cells [24]. In addition,
a recent study has reported that monocytes and comple-
ment system contributed to the tuberculosis-associated
immune reconstitution inflammatory syndrome in HIV-
TB co-infected patients [41]. Altogether, these studies
have demonstrated the importance of complement com-
ponents in HIV disease progression. Recently, another key
component of innate immunity, Toll-like receptor signal-
ing (TLR) pathway, has been found to be significantly
down-regulated in monocytes from viremic patients ver-
sus long-term non-progressors [23]. The different direc-
tion of the changes may reflect the various aspects of
HIV-host interactions that contribute to disease progres-
sion, such as HIV persistence and impairment of T cell
functions. Despite this difference, all of the aforemen-
tioned studies point towards the adaptive immunity being
perturbed at the interface where innate and adaptive im-
munity interact during HIV disease progression.
Consistent with the previous reports on phagocytosis
dysfunction in monocytes upon HIV infection [43-45], we
observed the significant up-regulation of FcγR-mediatedphagocytosis pathway (HSA04666) in the VIR group ver-
sus the BDL group (FDR = 0.029; Figure 4). The expres-
sion of FCGR1A (FcγRI/CD64), the sole high affinity
receptor for monomeric IgG, was coordinately increased
along with other core enrichment genes in the viremic pa-
tients. This observation was consistent with the previous
study reporting the increased expression of FcγRI on
monocytes from acute HIV infection patients compared
to chronically-infected individuals and healthy controls
[46]. In addition, the previous study suggested that mono-
cytes might expand and/or up-regulate the expression of
this high affinity FcγR in response to the burst of viral rep-
lication. This host response may also account for the in-
creased FCGR1A expression in the viremic patients on
HAART, as detected in this study.
The perturbation of phagocytosis pathway was further
manifested by the up-regulation of the genes encoding
for kinases in early signaling events such as SRC kinases
(HCK and LYN) and SYK, as well as the genes encoding
for proteins involved in oxidative burst (SPHK1/NADPH
oxidase) and cytoskeleton rearrangement (Table 5). The
Wu et al. Virology Journal 2013, 10:361 Page 12 of 16
http://www.virologyj.com/content/10/1/361majority of the core enrichment genes, which spread along
the signaling branches of PI3K – AKT, PIP5K – VASP/
WASP/WAVE – ARP2/3, and VAV – RAC – PAK1 –
CFL1, have also been implicated previously in HIV
pathogenesis. A recent study using gene knockdown and
pharmacological inhibition of SRC and AKT identified
them as mediators of HIV-induced inhibition of autopha-
gocytosis in bystander macrophages/monocytic cells [47].
The elevated AKT activity was also detected in HIV-
infected macrophages, and PI3K/AKT inhibitors were
suggested as a novel therapy for interfering with the estab-
lishment of HIV reservoirs [48]. In the signaling branch
pointing towards ARP2/3, WAVE2 was involved in the ac-
tivation of the actin polymerization nucleator ARP2/3
complex, which played a role in the migration of the viral
core components toward the cell nucleus and the efficient
infection of HIV in cell lines [49,50]. In addition, HIV
Nef was found to activate the signaling branch of VAV –
RAC – PAK (p21), which markedly enhanced the
NADPH oxidase response [51]. Nef also mediated CFL1
phosphorylation, which was crucial for maintaining
actin homeostasis [52]. Taken together, the up-regulated
expression of the genes involved in various kinase cas-
cades and the gene encoding for FcγRI may reflect the
HIV interference with the host genetic machinery on
the one hand, and the compensatory processes adapted
by the host on the other hand during virological failure.
Chemokine signaling pathway (HSA04062) was also
significantly up-regulated in the VIR group versus the
BDL group (FDR = 0.038), which was manifested by the
systematic up-regulation of the genes encoding for
chemokine ligand 2 (CCL2/MCP-1) and chemokine re-
ceptors including CCR1, CCR2, CCR3, CCR7, CCR9,
CX3CR1, CXCR5, and XCR1 (Table 5; Figure 5). The
up-regulation of MCP-1 in viremic patients was also re-
ported by Pulliam et al. [20], which was suggested to be
involved in enhancing HIV production and spread [53].
In addition, it was shown that the sequential activation
of SRC, MAPKs, and PI3K – AKT – NFκB pathways re-
sulted in the increased expression of MCP-1 [54]. Given
the fact that the majority of these genes overlapped with
the core enrichment genes we detected, it is thus plaus-
ible to hypothesize that the up-regulation of MAPK and
NFκB braches signaling through Gα subunit may be re-
lated to the coordinated up-regulation of MCP-1, which
could contribute to HIV spread. This potential link could
be one of the mechanisms underlying the association of
the up-regulation of chemokine signaling pathway with
virological failure during HAART.
In the comparison of VIR versus BDL, the promoter
motif analysis yielded a list of significantly up- and down-
regulated gene sets with members of each gene set
containing the same binding site for a certain transcrip-
tion factor (Additional file 4). The transcription factorsimplicated by these significant gene sets included some of
the well-known regulators, such as SP (SP1 and SP3),
NFκB (RELA binding motif), AP1, AP2, and CREB1,
which have been demonstrated to play crucial roles in
HIV transcription regulation [17]. Interestingly, the
most significantly up-regulated gene set in the VIR
group (FDR = 0.03) contained the binding motif for
RELA, which was also identified as the core enrichment
gene in chemokine signaling pathway in the VIR group.
This overlap not only demonstrated the consistency be-
tween pathway and promoter motif analysis, but also
implicated the complexity of the transcriptional regula-
tion underlying HIV-monocyte interaction. In addition
to the aforementioned transcription factors, some of the
significant gene sets contained the binding motifs with-
out matching any known transcription factor, which
may suggest potential novel regulators that warrant fu-
ture investigations.
A few limitations of this study should be noted. First,
this study used a cross-sectional design, which could not
provide dynamic findings from a longitudinal perspec-
tive. Secondly, this study used a relatively small sample
size appropriate for the pilot investigation and future
studies using larger sample size are thus warranted to
further confirm the results. Finally, although the GSEA
identified a panel of significantly altered gene sets with
high relevance to HIV disease progression during therapy,
the predictive nature of GSEA as the common limitation
of statistical tools should be noted and interpretations
should be made with caution. To overcome this limitation,
future biological experiments should be conducted to dir-
ectly confirm and further explore these findings.
Conclusions
This study has revealed the first transcriptome distinctions
in monocytes between HIV+ patients on HAART who
consecutively experienced plasma viremia and HIV+ pa-
tients on HAART who sustainably controlled plasma
viremia to below detection level. Compared to the BDL
group, the pathways characterizing the primary functions
of monocytes including antigen processing and presenta-
tion, FcγR mediated phagocytosis, and chemokine signal-
ing, were significantly up-regulated in the VIR group. Our
results reflected the outcome balanced between the sub-
version of monocyte transcriptome by HIV and the com-
pensatory effects adapted by host cells. Furthermore, the
altered pathways of antigen presentation and complement
cascade highlighted that HIV manipulated adaptive im-
mune response via innate immunity components at the
interface of innate-adaptive immunity during disease pro-
gression. These data offered new comparative insights into
the perturbed genetic networks of ex vivo-derived mono-
cytes subverted by HIV during disease progression on
therapy. In-depth functional studies on the regulation of
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http://www.virologyj.com/content/10/1/361these pathways and the corresponding core enrichment
genes along with proteomic analysis may further confirm
our findings and provide detailed molecular mechanisms
underlying HIV-monocyte interaction.
Methods
Patient profiles and collection protocol
Five HIV+ patients on HAART who sustainably con-
trolled HIV to below detection level (viral load < 40 cop-
ies of HIV RNA/ml), five HIV+ patients on HAART who
consecutively experienced viremia, and four healthy HIV
sero-negative controls were studied (Table 1). Patients
with viral load < 1,000 were chosen to represent patients
on HAART with virological failure because the previous
study has demonstrated that the transcriptome profiling
of these patients was more homogenous [23]. It has also
been shown that monocyte transcriptomes from patients
with viral load < 1,000 and those with higher viral load
exhibited similar dysregulated pathways during disease
progression. Patients in the VIR and BDL groups were
on HAART for > 52 weeks. The BDL and VIR groups
had a broad range of CD4+ T cell counts (100–796
cells/μl) as our objective was to find unbiased differences
of gene expression profiling of monocytes between pa-
tients on HAART with sustained virus suppression and
virological failure regardless of the degree of T cell de-
cline. This grouping criterion by viral load has been suc-
cessfully used by the previous studies [20,23,24]. These
patients received two NRTIs (zidovudine, lamivudine,
stavudine, emtricitabine, tenofovir) in association with
one or two protease inhibitors (darunavir, ritonavir, in-
dinavir, saquinavir, atazanavir). Ten patients were from
the HIV clinic at Westmead Hospital and the four healthy
controls were from the Australian Red Cross Blood Ser-
vice in Sydney. This study was approved by the Sydney
West Area Health Services Research Ethics Committee,
and all blood samples were collected after individual in-
formed written consent.
Purification of CD14+ monocytes and RNA isolation
A single blood sample (10–20 ml in EDTA) was ob-
tained from each patient. After separation of plasma,
primary PBMCs were isolated immediately after obtain-
ing blood samples by Ficoll-gradient centrifugation and
purified. This aspect was strictly followed in our experi-
ments because of previously described lower RNA yields
and possible changes in gene expression profiles upon
storage of blood [55]. CD14+ monocytes were then ob-
tained by positive isolation with antibody-conjugated
magnetic beads according to the manufacturer’s instruc-
tions (Miltenyi Biotech, Germany) with a purity > 98.6%
as verified by flow cytometry. Binding of antibody to
CD14 does not trigger signal transduction and a previ-
ous study has clearly demonstrated that CD14 positiveselection does not alter cellular transcriptome by com-
paring gene expression profiles in parallel using either
positive or negative selection [55]. Total RNA was iso-
lated from purified cells using RNeasy Mini kit (Qiagen
Pty Ltd., Clifton Hill, Victoria, Australia) with an inte-
grated step of on-column DNase treatment.
cRNA preparation, microarray hybridization and scanning
RNA quality was checked by Agilent Bioanalyzer and
RNA Integrity Scores were higher than 9 for all the
samples (Table 1). cRNA amplification and labeling with
biotin were performed using Illumina TotalPrep RNA
amplification kit (Ambion, Inc., Austin, USA) with 250 ng
total RNA as input material. cRNA yields were quantified
with Agilent Bioanalyzer and 750 ng cRNAs were hybrid-
ized to Illumina HumanHT-12 v3 Expression BeadChips
(Illumina, Inc., San Diego, USA). Each chip contains 12 ar-
rays and each array contains >48,000 gene transcripts, of
which, 46,000 are derived from human genes in the
National Center for Biotechnology Information (NCBI)
Reference Sequence (RefSeq) and UniGene databases. All
reagents and equipment used for hybridization were pur-
chased from Illumina, Inc. According to the manufac-
turer’s protocol, cRNAs were hybridized to arrays for
16 hours at 58°C before being washed and stained with
streptavidin-Cy3. Then the beadchips were centrifuged to
dry and scanned on the Illumina BeadArray Reader con-
focal scanner. To minimize the batch effect, the micro-
array chips were all processed at the single site using the
same platform with the identical setting of the parameters
by the same experimenter. The microarray dataset has
been submitted to GEO (Accession Number GSE52900).
Analysis of differentially expressed genes
The quality of the entire data set was assessed by box plot
and density plot of bead intensities, density plot of coeffi-
cient of variance, pairwise MAplot, pairwise plot with
microarray correlation, cluster dendrogram, and non-
metric multidimensional scaling using R/Bioconductor
and the lumi package [56]. Based on the quality assess-
ment, all 14 samples were deemed suitable for further
analysis. Data normalization was performed using log2
transform and a robust spline normalization (RSN) imple-
mented in the lumi package for R/Bioconductor [56,57].
Cluster analysis of gene expression profiling was carried
out using dist and hclust functions from R stats package.
Euclidean distance and complete linkage were used for
distance metric and linkage criterion, respectively. To re-
duce false positives of differentially expressed genes, genes
below detectable limit (based on a detection p value cut-
off 0.01) were removed from the dataset. A linear model
fit in conjunction with an empirical Bayes statistics was
used to identify candidate DEGs [58]. P values were
corrected for multiple testing using FDR adjustment
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the 3 groups were carried out and candidate DEGs with
fold change >2 and FDR <0.05 were identified for each of
the comparisons. The list of the DEGs derived from the
comparison of VIR versus BDL was uploaded to DAVID
for the detection of the DEGs showing overlap with the
genes in HIV interaction database at NCBI [59,60].
Gene set enrichment analysis
GSEA was used for the comparison of our dataset with
the published DEG lists from the previous studies (in vivo
and ex vivo since 2002) [15,16,19,21,22,27-30], the investi-
gation of global dysregulations of the biological pathways,
and the promoter motif analysis. For the comparison with
previous studies, 10 DEG lists were used from the studies
on monocyte/MDM transcriptomes modulated by HIV
(Table 4). For the pathway investigation, the gene sets
were from MsigDB [32], catalog C2 functional sets, subca-
talog KEGG pathways, which included 186 gene sets from
pathway databases. For the promoter motif analysis, C3
motif gene sets which contained gene members sharing
the same transcription factor binding site were used. This
collection included 615 gene sets and each of them was
annotated by a TRANSFAC record [33,61].
Instead of focusing on discrete DEGs, we analyzed the
entire transcriptome data with GSEA to identify genes
coordinately regulated in predefined gene sets from vari-
ous biological pathways [32]. For each group compari-
son, GSEA was performed using the normalized data of
entire 48,803 transcripts (GSEA version 2.07, Broad
Institute http://www.broad.mit.edu/gsea). First, a ranked
list was obtained by ranking all genes according to the
correlation between their expression and the group dis-
tinction using the metric signal to noise ratio. Then the
association between a given gene set and the group was
measured by the non-parametric running sum statistic
termed the enrichment score (ES), which was calculated
by walking down the ranked list (increasing ES when en-
countering a gene in the given gene set and decreasing
ES when encountering a gene not in the gene set). To
estimate the statistical significance of the ES, a nominal
p value was calculated by permuting the genes 1,000
times. To adjust for multiple hypothesis testing, the max-
imum ES was normalized to account for the gene set size
(NES) and the false discovery rate (FDR) corresponding to
each NES was also calculated. Along with the pathway en-
richment results, the details report for each significant
pathway was simultaneously generated. This report listed
the details of each gene member in columns, one of which
indicated whether this gene member was “core enrich-
ment gene” or not. The core enrichment genes account
for the enrichment signal of the pathway and the inspec-
tion of them can reveal a biologically important subset
within the pathway [32].Real-time quantitative PCR
Ten genes and 14 pairs of group comparison were selected
for validation based on the coverage of different levels and
directions of fold change, different ranges of FDR values,
and/or biological significance. Purified total cellular RNA
was used for reverse transcription with oligo d (T) and
Superscript III followed by RNase H treatment (Invitrogen
Life Technologies). The cDNA was then subjected to qPCR
in a 96-well format in triplicate reactions with defined
primers and SYBR Green (Invitrogen Life Technologies).
The qPCR reactions were carried out for the extended co-
hort consisting of 10 viremic patients, 10 BDLs, and 9
healthy controls (including all the original samples used in
the microarray) using Mx3005P™ QPCR System (Strata-
gene). The mean expressions of the tested genes in each
group were obtained and the housekeeping gene GAPDH
was used as an internal control and the normalizer for all
data. The fold change was calculated by the relative quanti-
tation method 2-(ddCt). Primer sequences for each transcript
are available from the authors upon request.
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